Latest Healthcare Research Reports

Tag: acute respiratory distress syndrome market research

  • Acute Respiratory Distress Syndrome (ARDS) Market Growth Outlook Reveals A CAGR Of 11.7% And A Market Value Of $2.42 Billion By 2030

    Acute Respiratory Distress Syndrome (ARDS) Market Growth Outlook Reveals A CAGR Of 11.7% And A Market Value Of $2.42 Billion By 2030

    Delivering more actionable and strategically valuable research, The Business Research Company’s 2026 market reports feature market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights.

    Acute Respiratory Distress Syndrome (ARDS) Market Revenue Growth Supported By A CAGR Of 2.42% Through 2030

    The market for acute respiratory distress syndrome (ARDS) has experienced substantial expansion lately, projected to climb from $1.41 billion in 2025 to $1.56 billion by 2026, reflecting a compound annual growth rate of 10.5%. This upward trajectory in the historical period is largely due to a surge in respiratory infections, enhanced intensive care unit capacity within hospitals, greater dissemination of ARDS management guidelines, the restricted accessibility of sophisticated ventilation technology, and the increasing implementation of palliative care strategies.

    The global market for Acute Respiratory Distress Syndrome (ARDS) is poised for significant expansion over the coming years, projecting a valuation of $2.42 billion by 2030, driven by a compound annual growth rate of 11.7%. This anticipated growth is underpinned by several key factors, including innovations in mechanical ventilation and extracorporeal membrane oxygenation (ECMO) technologies, heightened research and development efforts in ARDS therapies, the expansion of critical care facilities worldwide, increased investment in tailored patient management approaches, and the rising incidence of severe pneumonia and sepsis. Emerging trends expected to shape the market during this period involve the growing utilization of mechanical ventilation and ECMO devices, a higher prevalence of ARDS stemming from COVID-19 and other respiratory ailments, the increased deployment of sophisticated diagnostic tools for earlier identification, the expansion of critical care and intensive care unit capacities, and a pronounced emphasis on individualized and supportive care strategies.

    Download A Free Sample Report For Comprehensive Market Insights:

    https://www.thebusinessresearchcompany.com/sample.aspx?id=13005&type=smp

    #Acute Respiratory Distress Syndrome (ARDS) Market Demand Drivers Creating New Revenue Opportunities

    A rise in respiratory ailments is anticipated to fuel the expansion of the acute respiratory distress syndrome (ARDS) market. Respiratory illnesses encompass a range of conditions affecting the respiratory tract, such as the airways and lungs, and can lead to breathing challenges. The growing prevalence of these conditions, exemplified by COVID-19, stands as a primary catalyst for the advancement of the ARDS market. Consequently, as more individuals contract respiratory illnesses, the need for treatments and therapeutic interventions for ARDS is projected to escalate, thereby stimulating market growth. For example, data from the National Asthma Council in Australia, a non-profit entity, indicated that in 2023, the nation witnessed 474 fatalities attributed to asthma, with 325 being female and 149 male. This number closely mirrors the 473 asthma-related deaths recorded in 2022, underscoring a stable pattern in asthma mortality across these two years. Thus, the escalating incidence of respiratory illnesses is demonstrably contributing to the growth trajectory of the ARDS market.

    Acute Respiratory Distress Syndrome (ARDS) Market Segment Analysis And Revenue Opportunities

    The acute respiratory distress syndrome (ards) market covered in this report is segmented –

    1) By Type: Diagnosis, Treatment

    2) By Cause: COVID-19 Disease 2019 (COVID-19), Sepsis, Inhalation Of Harmful Substances, Severe Pneumonia, Other Causes

    3) By Severity: Mild, Moderate, Severe

    4) By End User: Hospitals, Clinics, Ambulatory Service Centers, Other End Users

    Subsegments:

    1) By Diagnosis: Imaging Tests, Blood Tests

    2) By Treatment: Mechanical Ventilation, Medications, Extracorporeal Membrane Oxygenation (ECMO), Supportive Care

    Acute Respiratory Distress Syndrome (ARDS) Market Trends Driving Strategic Industry Expansion

    Key players in the acute respiratory distress syndrome market are concentrating their efforts on creating sophisticated immune-modulating treatments to boost patient survival rates and mitigate inflammation. These immune modulators function by re-establishing equilibrium within the immune system, specifically addressing flawed inflammatory processes rather than broadly depressing immune responses. A prime example is BioAegis Therapeutics, a US clinical-stage entity, which obtained FDA Fast Track designation in June 2025 for rhu-pGSN, their experimental therapy aimed at ARDS. This treatment’s mechanism involves restoring levels of gelsolin, an essential protein for immune regulation, thereby overseeing the activation of the NLRP3 inflammasome, improving the body’s ability to clear pathogens, eliminating harmful actin and inflammatory substances, and controlling macrophage behavior. Currently undergoing assessment in a comprehensive global Phase 2b study involving 600 participants with moderate to severe ARDS, rhu-pGSN might also become accessible via the FDA’s Expanded Access or Compassionate Use pathways. The Fast Track status facilitates a more streamlined regulatory review process, allows for the submission of marketing applications in stages, and qualifies the therapy for priority review, which could significantly shorten its journey to market and present a groundbreaking treatment avenue for individuals facing dire medical circumstances with few other options.

    Acute Respiratory Distress Syndrome (ARDS) Market Leading Players Shaping Industry Direction

    Major companies operating in the acute respiratory distress syndrome (ards) market are Johnson & Johnson Services Inc., Novartis AG, GlaxoSmithKline plc, Medtronic plc, Boehringer Ingelheim International GmbH, Gilead Sciences Inc., Amgen Inc., Fresenius SE & Co. KGaA, Koninklijke Philips N.V., Baxter International Inc., Teva Pharmaceutical Industries Ltd., CSL Behring, Terumo Corporation, Smiths Medical Inc., Dräger Safety AG & Co. KGaA, Getinge AB, Mallinckrodt plc, Masimo Corporation, Fisher & Paykel Healthcare Corporation Limited, Hamilton Medical AG, Windtree Therapeutics Inc., Faron Pharmaceuticals Oy

    Access The Complete Acute Respiratory Distress Syndrome (ARDS) Market Report:

    https://www.thebusinessresearchcompany.com/report/acute-respiratory-distress-syndrome-ards-global-market-report

    Acute Respiratory Distress Syndrome (ARDS) Market Geographic Landscape: Which Region Dominates Industry Growth?

    North Americawas the largest region in the acute respiratory distress syndrome (ARDS) market in 2025. The regions covered in the acute respiratory distress syndrome (ards) market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

    Get in touch with us:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas: +1 310-496-7795

    Asia: +44 7882 955267 & +91 8897263534

    Europe: +44 7882 955267

    Email us at: marketing@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

  • Acute Respiratory Distress Syndrome (ARDS) Market Expected To Witness Revenue Growth Toward $2.42 Billion By 2030

    Acute Respiratory Distress Syndrome (ARDS) Market Expected To Witness Revenue Growth Toward $2.42 Billion By 2030

    The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

    What Market Size Is Forecasted For The Acute Respiratory Distress Syndrome (ARDS) Market By 2030 Based On Its 2026 Value?

    The market size for acute respiratory distress syndrome (ards) has expanded swiftly in recent years. Projections indicate it will increase from $1.41 billion in 2025 to $1.56 billion in 2026, achieving a compound annual growth rate (CAGR) of 10.5%. Historically, this expansion can be attributed to the rising incidence of respiratory infections, growing hospital icu infrastructure, increasing awareness of ards management protocols, limited availability of advanced ventilation devices, and adoption of supportive care practices.

    The acute respiratory distress syndrome (ARDS) market size is set to experience significant growth in the upcoming years. It is projected to reach $2.42 billion by 2030, with a compound annual growth rate (CAGR) of 11.7%. The expansion during this forecast period can be attributed to advancements in mechanical ventilation and ECMO systems, increasing research and development in ARDS therapeutics, the global proliferation of critical care units, rising investment in customized patient management solutions, and the growing incidence of severe pneumonia and sepsis. Major trends expected in the forecast period include a greater adoption of mechanical ventilation and ECMO devices, an increase in ARDS prevalence due to COVID-19 and other respiratory conditions, the expanding utilization of advanced diagnostic tests for early detection, an expansion of critical care and ICU facilities, and a focus on personalized and supportive care management.

    Download A Free Sample Report For Comprehensive Market Insights:

    https://www.thebusinessresearchcompany.com/sample.aspx?id=13005&type=smp

    What Core Drivers Are Transforming The Acute Respiratory Distress Syndrome (ARDS) Market?

    The acute respiratory distress syndrome (ARDS) market is expected to witness growth moving forward due to the rising prevalence of respiratory illnesses. Respiratory illness refers to a variety of medical conditions that impact the respiratory system, including the airways and lungs, often resulting in breathing difficulties. The increased occurrence of respiratory illnesses, such as COVID-19, stands as a primary catalyst for the expansion of the acute respiratory distress syndrome (ARDS) market. As more individuals develop respiratory illnesses, the demand for ARDS treatments and therapies is anticipated to climb, fostering market growth. For instance, in October 2024, information from the National Asthma Council, an Australia-based non-profit organization, revealed that Australia recorded 474 asthma-related deaths in 2023, consisting of 325 females and 149 males. This figure is nearly identical to the 473 asthma-related deaths reported in 2022, indicating a consistent trend in asthma mortality over the two-year period. Thus, the escalating number of respiratory illnesses is propelling the growth of the acute respiratory distress syndrome (ARDS) market.

    How Are Different Segment Groups Identified Within The Acute Respiratory Distress Syndrome (ARDS) Market?

    The acute respiratory distress syndrome (ards) market covered in this report is segmented –

    1) By Type: Diagnosis, Treatment

    2) By Cause: COVID-19 Disease 2019 (COVID-19), Sepsis, Inhalation Of Harmful Substances, Severe Pneumonia, Other Causes

    3) By Severity: Mild, Moderate, Severe

    4) By End User: Hospitals, Clinics, Ambulatory Service Centers, Other End Users

    Subsegments:

    1) By Diagnosis: Imaging Tests, Blood Tests

    2) By Treatment: Mechanical Ventilation, Medications, Extracorporeal Membrane Oxygenation (ECMO), Supportive Care

    Which Trends Are Affecting The Acute Respiratory Distress Syndrome (ARDS) Market Framework?

    Within the acute respiratory distress syndrome market, leading companies are concentrating on creating sophisticated immune modulators with the goal of improving patient survival rates and decreasing inflammation. These immune modulators function as treatments designed to restore the immune system’s equilibrium by addressing dysfunctional inflammatory pathways, all while avoiding the suppression of overall immune function. An illustrative example is BioAegis Therapeutics, a clinical-stage firm from the US, which in June 2025, secured FDA Fast Track designation for recombinant human plasma gelsolin (rhu-pGSN), its primary product intended for ARDS treatment. This particular therapy operates by restoring gelsolin, an essential immune regulatory protein, thereby modulating the activation of the NLRP3 inflammasome, boosting microbial clearance, eliminating harmful actin and inflammatory mediators, and regulating macrophage activity. Currently, rhu-pGSN is undergoing assessment in a global Phase 2b trial involving 600 patients suffering from moderate to severe ARDS, and it could also be accessible via the FDA Expanded Access or Compassionate Use program. Such Fast Track status facilitates quicker regulatory discussions, permits a rolling review process for marketing applications, and makes it eligible for priority review, which could potentially expedite its market entry and provide a new treatment choice for patients who have few other options.

    Which Organizations Are Operating Within The Acute Respiratory Distress Syndrome (ARDS) Market?

    Major companies operating in the acute respiratory distress syndrome (ards) market are Johnson & Johnson Services Inc., Novartis AG, GlaxoSmithKline plc, Medtronic plc, Boehringer Ingelheim International GmbH, Gilead Sciences Inc., Amgen Inc., Fresenius SE & Co. KGaA, Koninklijke Philips N.V., Baxter International Inc., Teva Pharmaceutical Industries Ltd., CSL Behring, Terumo Corporation, Smiths Medical Inc., Dräger Safety AG & Co. KGaA, Getinge AB, Mallinckrodt plc, Masimo Corporation, Fisher & Paykel Healthcare Corporation Limited, Hamilton Medical AG, Windtree Therapeutics Inc., Faron Pharmaceuticals Oy

    Access The Complete Acute Respiratory Distress Syndrome (ARDS) Market Report:

    https://www.thebusinessresearchcompany.com/report/acute-respiratory-distress-syndrome-ards-global-market-report

    Which Region Leads The Acute Respiratory Distress Syndrome (ARDS) Market By Size?

    North America was the largest region in the acute respiratory distress syndrome (ARDS) market in 2025. The regions covered in the acute respiratory distress syndrome (ards) market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

    Access Acute Respiratory Distress Syndrome (ARDS) Market Report for Deeper Competitive Insights

    https://www.thebusinessresearchcompany.com/customise?id=13005&type=smp

    Browse Through More Reports Similar to the Global Acute Respiratory Distress Syndrome (ARDS) Market 2026, By The Business Research Company

    Severe Acute Respiratory Syndrome Treatment Global Market Report 2026

    https://www.thebusinessresearchcompany.com/report/severe-acute-respiratory-syndrome-treatment-global-market-report

    Respiratory Disease Testing Global Market Report 2026

    https://www.thebusinessresearchcompany.com/report/respiratory-disease-testing-global-market-report

    Acute Coronary Syndrome Global Market Report 2026

    https://www.thebusinessresearchcompany.com/report/acute-coronary-syndrome-global-market-report

    Get in touch with us:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas: +1 310-496-7795

    Asia: +44 7882 955267 & +91 8897263534

    Europe: +44 7882 955267

    Email us at: marketing@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

  • ARDS Market to Reach $2.42B by 2030 at 11.7% CAGR

    ARDS Market to Reach $2.42B by 2030 at 11.7% CAGR

    The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

    By 2030, What Market Size Is The Acute Respiratory Distress Syndrome (ARDS) Market Expected To Reach Based On Its 2026 Value?

    The market size for acute respiratory distress syndrome (ards) has experienced significant expansion in recent years. It is anticipated to grow from $1.41 billion in 2025 to $1.56 billion in 2026, achieving a compound annual growth rate (CAGR) of 10.5%. The historical growth can be attributed to several factors including an increasing occurrence of respiratory infections, the expansion of hospital ICU infrastructure, greater understanding of ards management protocols, the constrained availability of advanced ventilation devices, and the widespread adoption of supportive care practices.

    The market for acute respiratory distress syndrome (ards) is expected to experience substantial expansion over the next few years. It is projected to achieve a size of $2.42 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 11.7%. This anticipated growth during the forecast period is fueled by factors such as technological progress in mechanical ventilation and ECMO systems, increased research and development in ARDS therapeutics, the global expansion of critical care units, rising investments in personalized patient management solutions, and the growing incidence of severe pneumonia and sepsis. Significant trends for the forecast period include the increasing adoption of mechanical ventilation and ECMO devices, a rise in the prevalence of ARDS due to COVID-19 and other respiratory illnesses, the expanding use of advanced diagnostic tests for early detection, the growth of critical care and ICU facilities, and a focus on personalized and supportive care management.

    Access Your Free Sample Report For In-Depth Market Analysis:

    https://www.thebusinessresearchcompany.com/report/acute-respiratory-distress-syndrome-ards-global-market-report

    What Key Factors Are Affecting The Acute Respiratory Distress Syndrome (ARDS) Market Demand?

    The growing incidence of respiratory illnesses is anticipated to propel the acute respiratory distress syndrome (ARDS) market forward. Respiratory illness encompasses a range of medical conditions affecting the respiratory system, including airways and lungs, which can lead to breathing difficulties. The escalating number of respiratory illnesses, exemplified by conditions such as COVID-19, is a primary catalyst driving the expansion of the acute respiratory distress syndrome (ARDS) market. As more individuals develop these illnesses, the demand for ARDS treatments and therapies is expected to rise, thereby stimulating market growth. For instance, in October 2024, the National Asthma Council, an Australia-based non-profit organization, reported that in 2023, Australia registered a total of 474 asthma-related deaths, comprising 325 females and 149 males. This total is almost identical to the 473 asthma-related deaths reported in 2022, indicating a consistent trend in asthma mortality over these two years. Consequently, the increasing prevalence of respiratory illnesses is a significant driver for the growth of the acute respiratory distress syndrome (ARDS) market.

    How Is The Acute Respiratory Distress Syndrome (ARDS) Market Segmented Across Different Segment Categories?

    The acute respiratory distress syndrome (ards) market covered in this report is segmented –

    1) By Type: Diagnosis, Treatment

    2) By Cause: COVID-19 Disease 2019 (COVID-19), Sepsis, Inhalation Of Harmful Substances, Severe Pneumonia, Other Causes

    3) By Severity: Mild, Moderate, Severe

    4) By End User: Hospitals, Clinics, Ambulatory Service Centers, Other End Users

    Subsegments:

    1) By Diagnosis: Imaging Tests, Blood Tests

    2) By Treatment: Mechanical Ventilation, Medications, Extracorporeal Membrane Oxygenation (ECMO), Supportive Care

    What Trends Are Influencing Changes In The Acute Respiratory Distress Syndrome (ARDS) Market?

    Companies at the forefront of the acute respiratory distress syndrome market are concentrating on developing advanced immune modulators to boost patient survival and decrease inflammation. Immune modulators are treatments designed to restore immune equilibrium by targeting dysfunctional inflammatory pathways without suppressing the body’s overall immune function. For instance, in June 2025, BioAegis Therapeutics, a US-based clinical-stage company, obtained FDA Fast Track designation for its primary product, recombinant human plasma gelsolin (rhu-pGSN), intended for the treatment of ARDS. This therapy functions by restocking gelsolin, a crucial immune regulatory protein, to modulate NLRP3 inflammasome activation, improve microbial clearance, remove toxic actin and inflammatory mediators, and regulate macrophage activity. rhu-pGSN is currently being evaluated in a 600-patient global Phase 2b trial for moderate to severe ARDS and may also become available through the FDA Expanded Access or Compassionate Use program. The Fast Track designation allows for accelerated regulatory interactions, a rolling review of marketing applications, and eligibility for priority review, potentially speeding up its market entry and providing a new therapeutic choice for patients with restricted alternatives.

    Which Organizations Play A Role In The Acute Respiratory Distress Syndrome (ARDS) Market Landscape?

    Major companies operating in the acute respiratory distress syndrome (ards) market are Johnson & Johnson Services Inc., Novartis AG, GlaxoSmithKline plc, Medtronic plc, Boehringer Ingelheim International GmbH, Gilead Sciences Inc., Amgen Inc., Fresenius SE & Co. KGaA, Koninklijke Philips N.V., Baxter International Inc., Teva Pharmaceutical Industries Ltd., CSL Behring, Terumo Corporation, Smiths Medical Inc., Dräger Safety AG & Co. KGaA, Getinge AB, Mallinckrodt plc, Masimo Corporation, Fisher & Paykel Healthcare Corporation Limited, Hamilton Medical AG, Windtree Therapeutics Inc., Faron Pharmaceuticals Oy

    Get The Full Acute Respiratory Distress Syndrome (ARDS) Market Report:

    https://www.thebusinessresearchcompany.com/report/acute-respiratory-distress-syndrome-ards-global-market-report

    Where Is The Acute Respiratory Distress Syndrome (ARDS) Market Primarily Concentrated By Region?

    North America was the largest region in the acute respiratory distress syndrome (ARDS) market in 2025. The regions covered in the acute respiratory distress syndrome (ards) market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

    Request A Customized Acute Respiratory Distress Syndrome (ARDS) Market Report For Competitive Insights:

    https://www.thebusinessresearchcompany.com/report/acute-respiratory-distress-syndrome-ards-global-market-report

    Browse Through More Reports Similar to the Global Acute Respiratory Distress Syndrome (ARDS) Market 2026, By The Business Research Company

    Acute Coronary Syndrome Market Report 2026

    https://www.thebusinessresearchcompany.com/report/acute-coronary-syndrome-global-market-report

    Severe Acute Respiratory Syndrome Treatment Market Report 2026

    https://www.thebusinessresearchcompany.com/report/severe-acute-respiratory-syndrome-treatment-global-market-report

    Respiratory Disease Testing Market Report 2026

    https://www.thebusinessresearchcompany.com/report/respiratory-disease-testing-global-market-report

    Get in touch with us:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas +1 310-496-7795

    Asia +44 7882 955267 & +91 8897263534

    Europe +44 7882 955267

    Email us at info@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

  • An Important Factor Driving the Acute Respiratory Distress Syndrome (ARDS) Market Global Report 2026 Market Is the Increasing Number Of Respiratory Illness Are Anticipated To Positively Impact The Acute Respiratory Distress Syndrome (ARDS) Market

    An Important Factor Driving the Acute Respiratory Distress Syndrome (ARDS) Market Global Report 2026 Market Is the Increasing Number Of Respiratory Illness Are Anticipated To Positively Impact The Acute Respiratory Distress Syndrome (ARDS) Market

    The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

    How Is The Market Size Of The Acute Respiratory Distress Syndrome (ARDS) Market Expected To Change Between 2026 And 2030?

    The market for acute respiratory distress syndrome (ards) has experienced swift expansion over recent years. Its valuation is set to increase from $1.41 billion in 2025 to $1.56 billion in 2026, with a compound annual growth rate (CAGR) of 10.5%. This historical growth can be attributed to several factors, including the rising incidence of respiratory infections, a growing hospital icu infrastructure, increasing awareness of ards management protocols, the limited availability of advanced ventilation devices, and the adoption of supportive care practices.

    The market for acute respiratory distress syndrome (ARDS) is projected to experience substantial expansion over the coming years, reaching $2.42 billion by 2030, driven by a compound annual growth rate (CAGR) of 11.7%. This anticipated growth is primarily due to technological innovations in mechanical ventilation and ECMO systems, heightened research and development efforts in ARDS therapeutics, the global expansion of critical care units, increased investment in customized patient management solutions, and the rising incidence of severe pneumonia and sepsis. Key trends anticipated during this period encompass the increased uptake of mechanical ventilation and ECMO devices, a higher prevalence of ARDS resulting from COVID-19 and other respiratory illnesses, the expanding application of sophisticated diagnostic tests for early identification, the growth of critical care and ICU infrastructure, and an emphasis on personalized and supportive patient care strategies.

    Download the Free Sample Report to Explore Key Market Insights:

    https://www.thebusinessresearchcompany.com/sample.aspx?id=13005&type=smp

    What Drivers Are Expected To Influence The Acute Respiratory Distress Syndrome (ARDS) Market During The Forecast Period?

    The rising prevalence of respiratory illnesses is projected to fuel the growth of the acute respiratory distress syndrome (ARDS) market moving forward. Respiratory illness refers to a collection of medical conditions that impact the respiratory system, including the airways and lungs, often causing breathing difficulties. The increasing number of respiratory illnesses, such as COVID-19, stands as a major factor propelling the expansion of the acute respiratory distress syndrome (ARDS) market. As more individuals contract respiratory illnesses, the need for ARDS treatments and therapies is expected to rise, thereby stimulating market growth. For instance, in October 2024, according to the National Asthma Council, an Australia-based non-profit organization, Australia recorded a total of 474 asthma-related deaths in 2023, consisting of 325 females and 149 males. This statistic is nearly identical to the 473 asthma-related deaths reported in 2022, highlighting a stable trend in asthma mortality over these two years. Consequently, the escalating number of respiratory illnesses is driving the growth of the acute respiratory distress syndrome (ARDS) market.

    How Is The Acute Respiratory Distress Syndrome (ARDS) Market Structured Across Different Segments?

    The acute respiratory distress syndrome (ards) market covered in this report is segmented –

    1) By Type: Diagnosis, Treatment

    2) By Cause: COVID-19 Disease 2019 (COVID-19), Sepsis, Inhalation Of Harmful Substances, Severe Pneumonia, Other Causes

    3) By Severity: Mild, Moderate, Severe

    4) By End User: Hospitals, Clinics, Ambulatory Service Centers, Other End Users

    Subsegments:

    1) By Diagnosis: Imaging Tests, Blood Tests

    2) By Treatment: Mechanical Ventilation, Medications, Extracorporeal Membrane Oxygenation (ECMO), Supportive Care

    Which Trends Are Shaping The Future Of The Acute Respiratory Distress Syndrome (ARDS) Market?

    Within the acute respiratory distress syndrome market, key companies are concentrating on creating sophisticated immune modulators with the goal of improving patient survival rates and diminishing inflammation. These immune modulators are therapeutic approaches designed to restore the immune system’s balance by addressing problematic inflammatory pathways, all without broadly suppressing immune function. An example of this is BioAegis Therapeutics, a clinical-stage company based in the US, which in June 2025, obtained FDA Fast Track designation for its primary candidate, recombinant human plasma gelsolin (rhu-pGSN), intended for the treatment of ARDS. This particular therapy functions by replenishing gelsolin, an essential protein for immune regulation, thereby regulating NLRP3 inflammasome activation, boosting microbial clearance, eliminating harmful actin and inflammatory agents, and controlling macrophage activity. The rhu-pGSN product is currently undergoing evaluation in a global Phase 2b trial involving 600 patients with moderate to severe ARDS, and it might also become accessible via the FDA Expanded Access or Compassionate Use program. The Fast Track designation provides several benefits, including streamlined regulatory interactions, a rolling review process for marketing applications, and qualification for priority review. These advantages could hasten its market entry and provide a new treatment choice for patients who have few other options.

    Which Major Players Dominate The Acute Respiratory Distress Syndrome (ARDS) Market?

    Major companies operating in the acute respiratory distress syndrome (ards) market are Johnson & Johnson Services Inc., Novartis AG, GlaxoSmithKline plc, Medtronic plc, Boehringer Ingelheim International GmbH, Gilead Sciences Inc., Amgen Inc., Fresenius SE & Co. KGaA, Koninklijke Philips N.V., Baxter International Inc., Teva Pharmaceutical Industries Ltd., CSL Behring, Terumo Corporation, Smiths Medical Inc., Dräger Safety AG & Co. KGaA, Getinge AB, Mallinckrodt plc, Masimo Corporation, Fisher & Paykel Healthcare Corporation Limited, Hamilton Medical AG, Windtree Therapeutics Inc., Faron Pharmaceuticals Oy

    Read the full acute respiratory distress syndrome (ards) market report here:

    https://www.thebusinessresearchcompany.com/report/acute-respiratory-distress-syndrome-ards-global-market-report

    Which Region Is Forecast To Lead The Acute Respiratory Distress Syndrome (ARDS) Market In Terms Of Market Size?

    North America was the largest region in the acute respiratory distress syndrome (ARDS) market in 2025. The regions covered in the acute respiratory distress syndrome (ards) market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

    Request A Tailored Acute Respiratory Distress Syndrome (ARDS) Market Research Report For Competitive Advantage:

    https://www.thebusinessresearchcompany.com/customise?id=13005&type=smp

    Browse Through More Reports Similar to the Global Acute Respiratory Distress Syndrome (ARDS) Market 2026, By The Business Research Company

    severe acute respiratory syndrome treatment global market report

    https://www.thebusinessresearchcompany.com/report/severe-acute-respiratory-syndrome-treatment-global-market-report

    respiratory disease testing global market report

    https://www.thebusinessresearchcompany.com/report/respiratory-disease-testing-global-market-report

    acute coronary syndrome global market report

    https://www.thebusinessresearchcompany.com/report/acute-coronary-syndrome-global-market-report

    Get in touch with us:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas +1 310-496-7795

    Asia +44 7882 955267 & +91 8897263534

    Europe +44 7882 955267

    Email us at info@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

  • Global Acute Respiratory Distress Syndrome (ARDS) Market Set for Strong Expansion, Reaching $2.42 Billion With 11.7% CAGR by 2030

    Global Acute Respiratory Distress Syndrome (ARDS) Market Set for Strong Expansion, Reaching $2.42 Billion With 11.7% CAGR by 2030

    Uncover key drivers, emerging technologies, and competitive movements shaping the acute respiratory distress syndrome (ards) market from 2026–2035 with trusted insights from The Business Research Company

    What total market size is anticipated for the Acute Respiratory Distress Syndrome (ARDS) Market in 2030?

    The acute respiratory distress syndrome (ards) market has experienced rapid expansion over recent years. Its size is projected to increase from $1.41 billion in 2025 to $1.56 billion in 2026, at a compound annual growth rate (CAGR) of 10.5%. This historical growth can be attributed to a rising incidence of respiratory infections, a growing hospital ICU infrastructure, increasing awareness of ARDS management protocols, limited availability of advanced ventilation devices, and the adoption of supportive care practices.

    The market size for acute respiratory distress syndrome (ards) is projected for substantial expansion over the coming years, reaching $2.42 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 11.7%. This anticipated growth is driven by technological progress in mechanical ventilation and ECMO systems, heightened research and development efforts in ARDS treatments, the global proliferation of critical care units, increasing investment in personalized patient management solutions, and the rising incidence of severe pneumonia and sepsis. Significant trends for this period encompass the growing adoption of mechanical ventilation and ECMO devices, an escalating prevalence of ARDS resulting from COVID-19 and other respiratory conditions, the expanded application of advanced diagnostic tests for early identification, the enlargement of critical care and ICU facilities, and a dedicated focus on personalized and supportive care management.

    Access Your Free Sample Report for In-Depth Market Insights:

    https://www.thebusinessresearchcompany.com/sample.aspx?id=13005&type=smp

    What Drivers Are Influencing Production Trends In The Acute Respiratory Distress Syndrome (ARDS) Market?

    The acute respiratory distress syndrome (ARDS) market is anticipated to expand due to a rising prevalence of respiratory illnesses. Respiratory illnesses encompass various medical conditions impacting the respiratory system, specifically the airways and lungs, often resulting in breathing difficulties. A key force behind the expansion of the acute respiratory distress syndrome (ARDS) market is the growing incidence of these conditions, exemplified by diseases such as COVID-19. This surge in respiratory ailments is projected to boost the need for ARDS treatments and therapies, consequently fostering market development. For example, data from October 2024, published by the National Asthma Council, an Australia-based non-profit body, revealed that Australia registered 474 asthma-related deaths in 2023, with 325 being females and 149 males. This mortality count closely mirrors the 473 asthma-related deaths documented in 2022, indicating a stable pattern in asthma fatalities over those two years. Consequently, the escalating occurrence of respiratory illnesses is a significant catalyst for the growth of the acute respiratory distress syndrome (ARDS) market.

    Which Segment Groups Are Influencing The Acute Respiratory Distress Syndrome (ARDS) Market?

    The acute respiratory distress syndrome (ards) market covered in this report is segmented –

    1) By Type: Diagnosis, Treatment

    2) By Cause: COVID-19 Disease 2019 (COVID-19), Sepsis, Inhalation Of Harmful Substances, Severe Pneumonia, Other Causes

    3) By Severity: Mild, Moderate, Severe

    4) By End User: Hospitals, Clinics, Ambulatory Service Centers, Other End Users

    Subsegments:

    1) By Diagnosis: Imaging Tests, Blood Tests

    2) By Treatment: Mechanical Ventilation, Medications, Extracorporeal Membrane Oxygenation (ECMO), Supportive Care

    Which Trends Are Guiding The Evolution Of The Acute Respiratory Distress Syndrome (ARDS) Market?

    Major companies operating in the acute respiratory distress syndrome market are concentrating on developing advanced immune modulators to improve patient survival and mitigate inflammation. These immune modulators are therapies designed to restore immune balance by targeting dysfunctional inflammatory pathways without suppressing overall immune function. For instance, in June 2025, BioAegis Therapeutics, a US-based clinical-stage company, received FDA Fast Track designation for its primary product, recombinant human plasma gelsolin (rhu-pGSN), intended for the treatment of ARDS. This therapy functions by replenishing gelsolin, which is a critical immune regulatory protein, to modulate NLRP3 inflammasome activation, enhance microbial clearance, remove toxic actin and inflammatory mediators, and regulate macrophage activity. rhu-pGSN is currently being evaluated in a 600-patient global Phase 2b trial for moderate to severe ARDS and may also be accessible through the FDA Expanded Access or Compassionate Use program. The Fast Track designation allows for expedited regulatory interactions, a rolling review of marketing applications, and eligibility for priority review, potentially accelerating its time to market and providing a novel therapeutic choice for patients with limited alternatives.

    Who Are The Core Companies Influencing Trends In The Acute Respiratory Distress Syndrome (ARDS) Market?

    Major companies operating in the acute respiratory distress syndrome (ards) market are Johnson & Johnson Services Inc., Novartis AG, GlaxoSmithKline plc, Medtronic plc, Boehringer Ingelheim International GmbH, Gilead Sciences Inc., Amgen Inc., Fresenius SE & Co. KGaA, Koninklijke Philips N.V., Baxter International Inc., Teva Pharmaceutical Industries Ltd., CSL Behring, Terumo Corporation, Smiths Medical Inc., Dräger Safety AG & Co. KGaA, Getinge AB, Mallinckrodt plc, Masimo Corporation, Fisher & Paykel Healthcare Corporation Limited, Hamilton Medical AG, Windtree Therapeutics Inc., Faron Pharmaceuticals Oy

    Access The Complete Report For Deeper Market Insights:

    https://www.thebusinessresearchcompany.com/report/acute-respiratory-distress-syndrome-ards-global-market-report

    Which Regions Are Projected To Dominate The Acute Respiratory Distress Syndrome (ARDS) Market In The Coming Years?

    North America was the largest region in the acute respiratory distress syndrome (ARDS) market in 2025. The regions covered in the acute respiratory distress syndrome (ards) market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

    Request Your Customized Acute Respiratory Distress Syndrome (ARDS) Market Research Report for Competitive Advantage:

    https://www.thebusinessresearchcompany.com/customise?id=13005&type=smp

    Browse Through More Reports Similar to the Global Acute Respiratory Distress Syndrome (ARDS) Market 2026, By The Business Research Company

    Acute Coronary Syndrome Market Report 2026

    https://www.thebusinessresearchcompany.com/report/acute-coronary-syndrome-global-market-report

    Severe Acute Respiratory Syndrome Treatment Market Report 2026

    https://www.thebusinessresearchcompany.com/report/severe-acute-respiratory-syndrome-treatment-global-market-report

    Respiratory Disease Testing Market Report 2026

    https://www.thebusinessresearchcompany.com/report/respiratory-disease-testing-global-market-report

    Get in touch with us:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas +1 310-496-7795

    Asia +44 7882 955267 & +91 8897263534

    Europe +44 7882 955267

    Email us at info@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

  • Global Acute Respiratory Distress Syndrome (ARDS) Market Set for Strong Expansion, Reaching $2.42 Billion With 11.7% CAGR by 2030

    Global Acute Respiratory Distress Syndrome (ARDS) Market Set for Strong Expansion, Reaching $2.42 Billion With 11.7% CAGR by 2030

    Uncover key drivers, emerging technologies, and competitive movements shaping the acute respiratory distress syndrome (ards) market from 2026–2035 with trusted insights from The Business Research Company

    What total market size is anticipated for the Acute Respiratory Distress Syndrome (ARDS) Market in 2030?

    The acute respiratory distress syndrome (ards) market has experienced rapid expansion over recent years. Its size is projected to increase from $1.41 billion in 2025 to $1.56 billion in 2026, at a compound annual growth rate (CAGR) of 10.5%. This historical growth can be attributed to a rising incidence of respiratory infections, a growing hospital ICU infrastructure, increasing awareness of ARDS management protocols, limited availability of advanced ventilation devices, and the adoption of supportive care practices.

    The market size for acute respiratory distress syndrome (ards) is projected for substantial expansion over the coming years, reaching $2.42 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 11.7%. This anticipated growth is driven by technological progress in mechanical ventilation and ECMO systems, heightened research and development efforts in ARDS treatments, the global proliferation of critical care units, increasing investment in personalized patient management solutions, and the rising incidence of severe pneumonia and sepsis. Significant trends for this period encompass the growing adoption of mechanical ventilation and ECMO devices, an escalating prevalence of ARDS resulting from COVID-19 and other respiratory conditions, the expanded application of advanced diagnostic tests for early identification, the enlargement of critical care and ICU facilities, and a dedicated focus on personalized and supportive care management.

    Access Your Free Sample Report for In-Depth Market Insights:

    https://www.thebusinessresearchcompany.com/sample.aspx?id=13005&type=smp

    What Drivers Are Influencing Production Trends In The Acute Respiratory Distress Syndrome (ARDS) Market?

    The acute respiratory distress syndrome (ARDS) market is anticipated to expand due to a rising prevalence of respiratory illnesses. Respiratory illnesses encompass various medical conditions impacting the respiratory system, specifically the airways and lungs, often resulting in breathing difficulties. A key force behind the expansion of the acute respiratory distress syndrome (ARDS) market is the growing incidence of these conditions, exemplified by diseases such as COVID-19. This surge in respiratory ailments is projected to boost the need for ARDS treatments and therapies, consequently fostering market development. For example, data from October 2024, published by the National Asthma Council, an Australia-based non-profit body, revealed that Australia registered 474 asthma-related deaths in 2023, with 325 being females and 149 males. This mortality count closely mirrors the 473 asthma-related deaths documented in 2022, indicating a stable pattern in asthma fatalities over those two years. Consequently, the escalating occurrence of respiratory illnesses is a significant catalyst for the growth of the acute respiratory distress syndrome (ARDS) market.

    Which Segment Groups Are Influencing The Acute Respiratory Distress Syndrome (ARDS) Market?

    The acute respiratory distress syndrome (ards) market covered in this report is segmented –

    1) By Type: Diagnosis, Treatment

    2) By Cause: COVID-19 Disease 2019 (COVID-19), Sepsis, Inhalation Of Harmful Substances, Severe Pneumonia, Other Causes

    3) By Severity: Mild, Moderate, Severe

    4) By End User: Hospitals, Clinics, Ambulatory Service Centers, Other End Users

    Subsegments:

    1) By Diagnosis: Imaging Tests, Blood Tests

    2) By Treatment: Mechanical Ventilation, Medications, Extracorporeal Membrane Oxygenation (ECMO), Supportive Care

    Which Trends Are Guiding The Evolution Of The Acute Respiratory Distress Syndrome (ARDS) Market?

    Major companies operating in the acute respiratory distress syndrome market are concentrating on developing advanced immune modulators to improve patient survival and mitigate inflammation. These immune modulators are therapies designed to restore immune balance by targeting dysfunctional inflammatory pathways without suppressing overall immune function. For instance, in June 2025, BioAegis Therapeutics, a US-based clinical-stage company, received FDA Fast Track designation for its primary product, recombinant human plasma gelsolin (rhu-pGSN), intended for the treatment of ARDS. This therapy functions by replenishing gelsolin, which is a critical immune regulatory protein, to modulate NLRP3 inflammasome activation, enhance microbial clearance, remove toxic actin and inflammatory mediators, and regulate macrophage activity. rhu-pGSN is currently being evaluated in a 600-patient global Phase 2b trial for moderate to severe ARDS and may also be accessible through the FDA Expanded Access or Compassionate Use program. The Fast Track designation allows for expedited regulatory interactions, a rolling review of marketing applications, and eligibility for priority review, potentially accelerating its time to market and providing a novel therapeutic choice for patients with limited alternatives.

    Who Are The Core Companies Influencing Trends In The Acute Respiratory Distress Syndrome (ARDS) Market?

    Major companies operating in the acute respiratory distress syndrome (ards) market are Johnson & Johnson Services Inc., Novartis AG, GlaxoSmithKline plc, Medtronic plc, Boehringer Ingelheim International GmbH, Gilead Sciences Inc., Amgen Inc., Fresenius SE & Co. KGaA, Koninklijke Philips N.V., Baxter International Inc., Teva Pharmaceutical Industries Ltd., CSL Behring, Terumo Corporation, Smiths Medical Inc., Dräger Safety AG & Co. KGaA, Getinge AB, Mallinckrodt plc, Masimo Corporation, Fisher & Paykel Healthcare Corporation Limited, Hamilton Medical AG, Windtree Therapeutics Inc., Faron Pharmaceuticals Oy

    Access The Complete Report For Deeper Market Insights:

    https://www.thebusinessresearchcompany.com/report/acute-respiratory-distress-syndrome-ards-global-market-report

    Which Regions Are Projected To Dominate The Acute Respiratory Distress Syndrome (ARDS) Market In The Coming Years?

    North America was the largest region in the acute respiratory distress syndrome (ARDS) market in 2025. The regions covered in the acute respiratory distress syndrome (ards) market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

    Request Your Customized Acute Respiratory Distress Syndrome (ARDS) Market Research Report for Competitive Advantage:

    https://www.thebusinessresearchcompany.com/customise?id=13005&type=smp

    Browse Through More Reports Similar to the Global Acute Respiratory Distress Syndrome (ARDS) Market 2026, By The Business Research Company

    Acute Coronary Syndrome Market Report 2026

    https://www.thebusinessresearchcompany.com/report/acute-coronary-syndrome-global-market-report

    Severe Acute Respiratory Syndrome Treatment Market Report 2026

    https://www.thebusinessresearchcompany.com/report/severe-acute-respiratory-syndrome-treatment-global-market-report

    Respiratory Disease Testing Market Report 2026

    https://www.thebusinessresearchcompany.com/report/respiratory-disease-testing-global-market-report

    Get in touch with us:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas +1 310-496-7795

    Asia +44 7882 955267 & +91 8897263534

    Europe +44 7882 955267

    Email us at info@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

  • Global Acute Respiratory Distress Syndrome (ARDS) Market Set for Strong Expansion, Reaching $2.42 Billion With 11.7% CAGR by 2030

    Global Acute Respiratory Distress Syndrome (ARDS) Market Set for Strong Expansion, Reaching $2.42 Billion With 11.7% CAGR by 2030

    Uncover key drivers, emerging technologies, and competitive movements shaping the acute respiratory distress syndrome (ards) market from 2026–2035 with trusted insights from The Business Research Company

    What total market size is anticipated for the Acute Respiratory Distress Syndrome (ARDS) Market in 2030?

    The acute respiratory distress syndrome (ards) market has experienced rapid expansion over recent years. Its size is projected to increase from $1.41 billion in 2025 to $1.56 billion in 2026, at a compound annual growth rate (CAGR) of 10.5%. This historical growth can be attributed to a rising incidence of respiratory infections, a growing hospital ICU infrastructure, increasing awareness of ARDS management protocols, limited availability of advanced ventilation devices, and the adoption of supportive care practices.

    The market size for acute respiratory distress syndrome (ards) is projected for substantial expansion over the coming years, reaching $2.42 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 11.7%. This anticipated growth is driven by technological progress in mechanical ventilation and ECMO systems, heightened research and development efforts in ARDS treatments, the global proliferation of critical care units, increasing investment in personalized patient management solutions, and the rising incidence of severe pneumonia and sepsis. Significant trends for this period encompass the growing adoption of mechanical ventilation and ECMO devices, an escalating prevalence of ARDS resulting from COVID-19 and other respiratory conditions, the expanded application of advanced diagnostic tests for early identification, the enlargement of critical care and ICU facilities, and a dedicated focus on personalized and supportive care management.

    Access Your Free Sample Report for In-Depth Market Insights:

    https://www.thebusinessresearchcompany.com/sample.aspx?id=13005&type=smp

    What Drivers Are Influencing Production Trends In The Acute Respiratory Distress Syndrome (ARDS) Market?

    The acute respiratory distress syndrome (ARDS) market is anticipated to expand due to a rising prevalence of respiratory illnesses. Respiratory illnesses encompass various medical conditions impacting the respiratory system, specifically the airways and lungs, often resulting in breathing difficulties. A key force behind the expansion of the acute respiratory distress syndrome (ARDS) market is the growing incidence of these conditions, exemplified by diseases such as COVID-19. This surge in respiratory ailments is projected to boost the need for ARDS treatments and therapies, consequently fostering market development. For example, data from October 2024, published by the National Asthma Council, an Australia-based non-profit body, revealed that Australia registered 474 asthma-related deaths in 2023, with 325 being females and 149 males. This mortality count closely mirrors the 473 asthma-related deaths documented in 2022, indicating a stable pattern in asthma fatalities over those two years. Consequently, the escalating occurrence of respiratory illnesses is a significant catalyst for the growth of the acute respiratory distress syndrome (ARDS) market.

    Which Segment Groups Are Influencing The Acute Respiratory Distress Syndrome (ARDS) Market?

    The acute respiratory distress syndrome (ards) market covered in this report is segmented –

    1) By Type: Diagnosis, Treatment

    2) By Cause: COVID-19 Disease 2019 (COVID-19), Sepsis, Inhalation Of Harmful Substances, Severe Pneumonia, Other Causes

    3) By Severity: Mild, Moderate, Severe

    4) By End User: Hospitals, Clinics, Ambulatory Service Centers, Other End Users

    Subsegments:

    1) By Diagnosis: Imaging Tests, Blood Tests

    2) By Treatment: Mechanical Ventilation, Medications, Extracorporeal Membrane Oxygenation (ECMO), Supportive Care

    Which Trends Are Guiding The Evolution Of The Acute Respiratory Distress Syndrome (ARDS) Market?

    Major companies operating in the acute respiratory distress syndrome market are concentrating on developing advanced immune modulators to improve patient survival and mitigate inflammation. These immune modulators are therapies designed to restore immune balance by targeting dysfunctional inflammatory pathways without suppressing overall immune function. For instance, in June 2025, BioAegis Therapeutics, a US-based clinical-stage company, received FDA Fast Track designation for its primary product, recombinant human plasma gelsolin (rhu-pGSN), intended for the treatment of ARDS. This therapy functions by replenishing gelsolin, which is a critical immune regulatory protein, to modulate NLRP3 inflammasome activation, enhance microbial clearance, remove toxic actin and inflammatory mediators, and regulate macrophage activity. rhu-pGSN is currently being evaluated in a 600-patient global Phase 2b trial for moderate to severe ARDS and may also be accessible through the FDA Expanded Access or Compassionate Use program. The Fast Track designation allows for expedited regulatory interactions, a rolling review of marketing applications, and eligibility for priority review, potentially accelerating its time to market and providing a novel therapeutic choice for patients with limited alternatives.

    Who Are The Core Companies Influencing Trends In The Acute Respiratory Distress Syndrome (ARDS) Market?

    Major companies operating in the acute respiratory distress syndrome (ards) market are Johnson & Johnson Services Inc., Novartis AG, GlaxoSmithKline plc, Medtronic plc, Boehringer Ingelheim International GmbH, Gilead Sciences Inc., Amgen Inc., Fresenius SE & Co. KGaA, Koninklijke Philips N.V., Baxter International Inc., Teva Pharmaceutical Industries Ltd., CSL Behring, Terumo Corporation, Smiths Medical Inc., Dräger Safety AG & Co. KGaA, Getinge AB, Mallinckrodt plc, Masimo Corporation, Fisher & Paykel Healthcare Corporation Limited, Hamilton Medical AG, Windtree Therapeutics Inc., Faron Pharmaceuticals Oy

    Access The Complete Report For Deeper Market Insights:

    https://www.thebusinessresearchcompany.com/report/acute-respiratory-distress-syndrome-ards-global-market-report

    Which Regions Are Projected To Dominate The Acute Respiratory Distress Syndrome (ARDS) Market In The Coming Years?

    North America was the largest region in the acute respiratory distress syndrome (ARDS) market in 2025. The regions covered in the acute respiratory distress syndrome (ards) market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

    Request Your Customized Acute Respiratory Distress Syndrome (ARDS) Market Research Report for Competitive Advantage:

    https://www.thebusinessresearchcompany.com/customise?id=13005&type=smp

    Browse Through More Reports Similar to the Global Acute Respiratory Distress Syndrome (ARDS) Market 2026, By The Business Research Company

    Acute Coronary Syndrome Market Report 2026

    https://www.thebusinessresearchcompany.com/report/acute-coronary-syndrome-global-market-report

    Severe Acute Respiratory Syndrome Treatment Market Report 2026

    https://www.thebusinessresearchcompany.com/report/severe-acute-respiratory-syndrome-treatment-global-market-report

    Respiratory Disease Testing Market Report 2026

    https://www.thebusinessresearchcompany.com/report/respiratory-disease-testing-global-market-report

    Get in touch with us:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas +1 310-496-7795

    Asia +44 7882 955267 & +91 8897263534

    Europe +44 7882 955267

    Email us at info@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

  • What Key Growth Drivers Are Shaping The Acute Respiratory Distress Syndrome (ARDS) Market Forecast Toward $2.15 Billion?

    What Key Growth Drivers Are Shaping The Acute Respiratory Distress Syndrome (ARDS) Market Forecast Toward $2.15 Billion?

    Claim your 20% discount on Global Market Reports with code ONLINE20. Limited time only.

    How Much Will The Acute Respiratory Distress Syndrome (ARDS) Market Be Worth By 2029?

    The market size for acute respiratory distress syndrome (ards) has seen substantial growth in recent years. The anticipated increase from $1.29 billion in 2024 to $1.41 billion in 2025, with a compound annual growth rate (CAGR) of 9.4%, indicates a strong market performance. Factors contributing to this significant growth include advances in critical care medicine, an increasing aging population, progress in pulmonary rehabilitation, and the effectiveness of multidisciplinary care teams.

    The market size for acute respiratory distress syndrome (ards) is projected to experience swift expansion over the upcoming years. The market is expected to reach a value of $2.15 billion by 2029, growing at a compound annual growth rate (CAGR) of 11.1%. This growth during the forecast period may be due to factors such as global preparedness for healthcare emergencies, advancements in vaccine production, and effective management of infectious diseases, along with the rise of telemedicine and remote patient monitoring, and development of patient-centric care models. Key trends for this period comprise artificial lung devices, individualized ventilation strategies, lung-protective ventilation techniques, and specific drug therapies for different ards types.

    Get A Free Sample Of The Report:

    https://www.thebusinessresearchcompany.com/sample.aspx?id=13005&type=smp

    What Market Forces Are Contributing To The Growth Of The Acute Respiratory Distress Syndrome (ARDS) Market?

    The escalating occurrence of pneumonia is anticipated to drive the expansion of the acute respiratory distress syndrome (ARDS) market in the future. Pneumonia is an infection that can infect one or both lungs, causing the air sacs, or alveoli, within the lungs to become filled with fluid or pus. This infection prompts an inflammatory response in the lungs, causing blood vessels to become more permeable and allowing fluid to leak into the alveoli. The accumulation of this fluid disrupts the exchange of oxygen and carbon dioxide, resulting in respiratory discomfort. For example, in November 2023, the Centre for Tropical Medicine and Global Health, a prominent healthcare research entity based in the UK, reported that the number of pneumonia cases in Kenya saw a considerable surge, reaching 793,864 in 2022-2023, a significant increase from 477,186 cases in 2020-2021. Therefore, the escalating occurrence of pneumonia is fuelling the growth of the acute respiratory distress syndrome (ARDS) market.

    Which Segments Define The Structure Of The Acute Respiratory Distress Syndrome (ARDS) Market?

    The acute respiratory distress syndrome (ards)market covered in this report is segmented –

    1) By Type: Diagnosis; Treatment

    2) By Cause: COVID-19 Disease 2019 (COVID-19); Sepsis; Inhalation Of Harmful Substances; Severe Pneumonia; Other Causes

    3) By Severity: Mild; Moderate; Severe

    4) By End User: Hospitals; Clinics; Ambulatory Service Centers; Other End Users

    Subsegments:

    1) By Diagnosis: Imaging Tests; Blood Tests; Lung Function Tests; Other Diagnostic Methods

    2) By Treatment: Mechanical Ventilation; Medications; Extracorporeal Membrane Oxygenation (ECMO); Supportive Care; Other Treatment Options

    Which Disruptive Trends Are Driving Change Across The Acute Respiratory Distress Syndrome (ARDS) Market?

    Leading firms in the acute respiratory distress syndrome (ARDS) market are concentrating their efforts on creating novel drugs and supplements such as Aviptadil, HSP90 inhibitors, among others, to maintain their market dominance. Aviptadil, a fabricated vasoactive intestinal peptide (VIP), specifically attaches to receptors located on lung alveolar type II cells. For example, Zuventus Healthcare Ltd, a pharmaceutical manufacturer from India, introduced Aviptadil in November 2022 to address acute respiratory distress syndrome. The supplement, being a vasoactive intestinal peptide, enhances breathing and reduces mortality rates in ARDS patients. This is made possible by Aviptadil’s capabilities to shield and rejuvenate Type-2 Pneumocytes, rehabilitate Type-1 Pneumocytes, boost surfactant synthesis, and inhibit IL-6 (interleukin 6) and the tumor necrosis factor (TNF)-alpha.

    Which Firms Are Making The Biggest Impact In The Acute Respiratory Distress Syndrome (ARDS) Market?

    Major companies operating in the acute respiratory distress syndrome (ards) market are Johnson & Johnson Services Inc., Novartis AG, GlaxoSmithKline PLC, Medtronic PLC, Boehringer Ingelheim International GmbH, Gilead Sciences Inc., Amgen Inc., Fresenius SE & Co. KGaA, Koninklijke Philips N.V., Baxter International Inc., Teva Pharmaceutical Industries Ltd., CSL Behring, Terumo Corporation, ResMed Inc., Smiths Medical Inc., Dräger Safety AG & Co. KGaA., Getinge AB, Mallinckrodt PLC, Masimo Corporation, United Therapeutics Corporation, Fisher & Paykel Healthcare Corporation Limited, Hamilton Medical AG, Zuventus Healthcare Ltd., Windtree Therapeutics Inc., Faron Pharmaceuticals Oy, AcelRx Pharmaceuticals Inc.

    Access The Complete Report Here:

    https://www.thebusinessresearchcompany.com/report/acute-respiratory-distress-syndrome-ards-global-market-report

    Which Region Is Forecasted To Lead The Acute Respiratory Distress Syndrome (ARDS) Market In The Coming Years?

    North America was the largest region in the acute respiratory distress syndrome (ARDS) market in 2024. The regions covered in acute respiratory distress syndrome (ARDS) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

    Customize Your Report Here:

    https://www.thebusinessresearchcompany.com/customise?id=13005&type=smp

    Browse Through More Reports Similar to the Global Acute Respiratory Distress Syndrome (ARDS) Market 2025, By The Business Research Company

    Respiratory Devices And Equipment Therapeutic And Diagnostic Global Market Report 2025

    https://www.thebusinessresearchcompany.com/report/respiratory-devices-and-equipment-therapeutic-and-diagnostic-global-market-report

    Respiratory Disposables Global Market Report 2025

    https://www.thebusinessresearchcompany.com/report/respiratory-disposables-global-market-report

    Respiratory Devices And Equipment Global Market Report 2025

    https://www.thebusinessresearchcompany.com/report/respiratory-devices-and-equipment-global-market-report

    About The Business Research Company:

    With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

    Get in touch with us:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas +1 310-496-7795

    Asia +44 7882 955267 & +91 8897263534

    Europe +44 7882 955267

    Email us at info@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

  • Acute Respiratory Distress Syndrome (ARDS) Market Growth Opportunities: Insights from 2025–2029

    Acute Respiratory Distress Syndrome (ARDS) Market Growth Opportunities: Insights from 2025–2029

    Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

    By How Much Is The Acute Respiratory Distress Syndrome (ARDS) Market Expected To Expand Between 2025 And 2029?

    The acute respiratory distress syndrome (ards) market size has demonstrated significant expansion in recent years. It is anticipated to grow from $1.29 billion in 2024 to $1.41 billion in 2025, exhibiting a compound annual growth rate (CAGR) of 9.4%. This historical growth can be attributed to advancements in critical care medicine, an aging population, progress in pulmonary rehabilitation, and the implementation of multidisciplinary care teams.

    The market for acute respiratory distress syndrome (ARDS) is projected to experience swift expansion over the coming years. This market is anticipated to reach $2.15 billion by 2029, exhibiting a compound annual growth rate (CAGR) of 11.1%. Several factors are expected to drive this growth during the forecast period, including advancements in global healthcare preparedness, the progress in vaccine development and infectious disease management, the expansion of telemedicine and remote monitoring, and the adoption of patient-centered care models. Key trends predicted for the forecast period encompass innovations like artificial lung devices, the implementation of personalized ventilation strategies, the widespread use of lung protective ventilation, and the development of targeted drug therapies for ARDS subtypes.

    Unlock Your Free Sample Report for Exclusive Market Data:

    https://www.thebusinessresearchcompany.com/sample.aspx?id=13005&type=smp

    Which Drivers Are Shaping The Acute Respiratory Distress Syndrome (ARDS) Industry’s Market Share?

    The increasing incidence of pneumonia is projected to drive the expansion of the acute respiratory distress syndrome (ARDS) market in the future. Pneumonia is an infection that impacts one or both lungs, resulting in the filling of the air sacs, or alveoli, with fluid or pus. This condition induces an inflammatory response within the lungs, which heightens blood vessel permeability and causes fluid to leak into the alveoli. Such fluid accumulation impedes the normal exchange of oxygen and carbon dioxide, leading to respiratory distress. For instance, in November 2023, reports from the Centre for Tropical Medicine and Global Health, a leading UK-based healthcare research organization, showed a significant surge in pneumonia cases in Kenya, reaching 793,864 in 2022-2023, an increase from 477,186 cases in 2020-2021. Thus, the escalating prevalence of pneumonia is a key driver for the growth of the acute respiratory distress syndrome (ARDS) market.

    What Are The Major Segment Categories Driving The Acute Respiratory Distress Syndrome (ARDS) Market Growth?

    The acute respiratory distress syndrome (ards)market covered in this report is segmented –

    1) By Type: Diagnosis; Treatment

    2) By Cause: COVID-19 Disease 2019 (COVID-19); Sepsis; Inhalation Of Harmful Substances; Severe Pneumonia; Other Causes

    3) By Severity: Mild; Moderate; Severe

    4) By End User: Hospitals; Clinics; Ambulatory Service Centers; Other End Users

    Subsegments:

    1) By Diagnosis: Imaging Tests; Blood Tests; Lung Function Tests; Other Diagnostic Methods

    2) By Treatment: Mechanical Ventilation; Medications; Extracorporeal Membrane Oxygenation (ECMO); Supportive Care; Other Treatment Options

    Which Key Trends Are Expected To Influence The Acute Respiratory Distress Syndrome (ARDS) Market In The Coming Years?

    Major companies operating in the acute respiratory distress syndrome (ARDS) market are prioritizing the creation of innovative drugs and supplements, including Aviptadil, HSP90 inhibitors, and others, to sustain their market presence. Aviptadil is a synthesized vasoactive intestinal peptide (VIP) that specifically attaches to receptors found on lung alveolar type II cells. For instance, in November 2022, Zuventus Healthcare Ltd., an India-based pharmaceutical manufacturing company, launched Aviptadil for treating acute respiratory distress syndrome. As a vasoactive intestinal peptide supplement, Aviptadil enhances respiration and reduces mortality in ARDS patients. This effect is achieved through Aviptadil’s ability to protect and regenerate Type-2 Pneumocytes, restore Type-1 Pneumocytes, boost surfactant synthesis, and suppress IL-6 (interleukin 6) and tumor necrosis factor (TNF)-alpha.

    Who Are The Core Companies Influencing The Acute Respiratory Distress Syndrome (ARDS) Market Landscape?

    Major companies operating in the acute respiratory distress syndrome (ards) market are Johnson & Johnson Services Inc., Novartis AG, GlaxoSmithKline PLC, Medtronic PLC, Boehringer Ingelheim International GmbH, Gilead Sciences Inc., Amgen Inc., Fresenius SE & Co. KGaA, Koninklijke Philips N.V., Baxter International Inc., Teva Pharmaceutical Industries Ltd., CSL Behring, Terumo Corporation, ResMed Inc., Smiths Medical Inc., Dräger Safety AG & Co. KGaA., Getinge AB, Mallinckrodt PLC, Masimo Corporation, United Therapeutics Corporation, Fisher & Paykel Healthcare Corporation Limited, Hamilton Medical AG, Zuventus Healthcare Ltd., Windtree Therapeutics Inc., Faron Pharmaceuticals Oy, AcelRx Pharmaceuticals Inc.

    Download The Full Report For Exclusive Market Findings:

    https://www.thebusinessresearchcompany.com/report/acute-respiratory-distress-syndrome-ards-global-market-report

    How Does The Acute Respiratory Distress Syndrome (ARDS) Market Perform Across Key Geographic Regions?

    North America was the largest region in the acute respiratory distress syndrome (ARDS) market in 2024. The regions covered in acute respiratory distress syndrome (ARDS) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

    Request A Customized Version Of The Acute Respiratory Distress Syndrome (ARDS) Market Report:

    https://www.thebusinessresearchcompany.com/customise?id=13005&type=smp

    Browse Through More Reports Similar to the Global Acute Respiratory Distress Syndrome (ARDS) Market 2025, By The Business Research Company

    Respiratory Devices And Equipment Therapeutic And Diagnostic Global Market Report 2025

    https://www.thebusinessresearchcompany.com/report/respiratory-devices-and-equipment-therapeutic-and-diagnostic-global-market-report

    Respiratory Disposables Global Market Report 2025

    https://www.thebusinessresearchcompany.com/report/respiratory-disposables-global-market-report

    Respiratory Devices And Equipment Global Market Report 2025

    https://www.thebusinessresearchcompany.com/report/respiratory-devices-and-equipment-global-market-report

    Get in touch with us:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas +1 310-496-7795

    Asia +44 7882 955267 & +91 8897263534

    Europe +44 7882 955267

    Email us at info@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

  • Major Drivers Propelling the Growth oh theAcute Respiratory Distress Syndrome (ARDS) Market Forward: Impact Of Increasing Pneumonia Prevalence On The Acute Respiratory Distress Syndrome (ARDS) Market

    Major Drivers Propelling the Growth oh theAcute Respiratory Distress Syndrome (ARDS) Market Forward: Impact Of Increasing Pneumonia Prevalence On The Acute Respiratory Distress Syndrome (ARDS) Market

    Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

    What Is the Estimated Market Size of the Acute Respiratory Distress Syndrome (ARDS) Market In 2029?

    The market size for acute respiratory distress syndrome (ARDS) has experienced robust growth in the recent past. It is projected to rise from $1.29 billion in 2024 to $1.41 billion in 2025, with a compound annual growth rate (CAGR) of 9.4%. Factors contributing to the historical growth include developments in critical care medicine, senior citizen population growth, advancements in rehabilitation for pulmonary conditions, and the use of multidisciplinary care teams.

    The market size for acute respiratory distress syndrome (ards) is projected to experience substantial expansion in the upcoming years, reaching$2.15 billion by 2029 with a compound annual growth rate (CAGR) of 11.1%. The reasons behind this growth during the predicted period are related to global preparedness for healthcare, advancement in vaccine development, managing infectious diseases, incorporation of telemedicine, and patient-centric care models. The upcoming trends for this period includes the use of artificial lung devices, customized ventilation methods, lung protection ventilation techniques, and drug treatments tailored for different ARDS subtypes.

    Download a free sample to assess the report’s scope and structure:

    https://www.thebusinessresearchcompany.com/sample.aspx?id=13005&type=smp

    Which Major Market Drivers Are Expected to Boost the Growth Potential of the Acute Respiratory Distress Syndrome (ARDS) Market?

    The surge in pneumonia cases is anticipated to stimulate the expansion of the acute respiratory distress syndrome (ARDS) market in the future. Pneumonia is a disease that can affect either one or both lungs, leading to the lung’s air pockets, known as alveoli, becoming filled with fluid or pus. The infection triggers an inflammatory response in the lungs, which heightens the permeability of blood vessels and causes fluid to leak into the alveoli. The accumulation of this fluid hampers the transfer of oxygen and carbon dioxide, resulting in respiratory distress. As an illustration, the Centre for Tropical Medicine and Global Health, a prominent UK-based healthcare research entity, reported a substantial increase in pneumonia cases in Kenya in November 2023, with the number skyrocketing to 793,864 in 2022-2023 from 477,186 in 2020-2021. Hence, the rising incidence of pneumonia is fueling the growth of the acute respiratory distress syndrome (ARDS) market.

    Which Key Market Segments Comprise the Acute Respiratory Distress Syndrome (ARDS) Market and Drive Its Revenue Growth?

    The acute respiratory distress syndrome (ards)market covered in this report is segmented –

    1) By Type: Diagnosis; Treatment

    2) By Cause: COVID-19 Disease 2019 (COVID-19); Sepsis; Inhalation Of Harmful Substances; Severe Pneumonia; Other Causes

    3) By Severity: Mild; Moderate; Severe

    4) By End User: Hospitals; Clinics; Ambulatory Service Centers; Other End Users

    Subsegments:

    1) By Diagnosis: Imaging Tests; Blood Tests; Lung Function Tests; Other Diagnostic Methods

    2) By Treatment: Mechanical Ventilation; Medications; Extracorporeal Membrane Oxygenation (ECMO); Supportive Care; Other Treatment Options

    Request customized data on this market:

    https://www.thebusinessresearchcompany.com/customise?id=13005&type=smp

    Which Areas Are Leading Regions in the Acute Respiratory Distress Syndrome (ARDS) Market Expansion Across the Globe?

    North America was the largest region in the acute respiratory distress syndrome (ARDS) market in 2024. The regions covered in acute respiratory distress syndrome (ARDS) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

    What Are the Key Market Trends in theAcute Respiratory Distress Syndrome (ARDS) Market Over the Coming Years?

    Big players in the acute respiratory distress syndrome (ARDS) market are aiming to maintain their market standing by creating novel drugs and supplements like Aviptadil, HSP90 inhibitors, and others. Aviptadil is a manufactured vasoactive intestinal peptide (VIP) that attaches distinctively to lung alveolar type II cell receptors. For example, in November 2022, Zuventus Healthcare Ltd., a pharmaceutical manufacturing firm in India, introduced Aviptadil for the treatment of acute respiratory distress syndrome. The supplement, a vasoactive intestinal peptide, boosts breathing and decreases fatality rates in ARDS patients through its capability to shield and regrow Type-2 Pneumocytes, replenish Type-1 Pneumocytes, amplify surfactant synthesis, and inhibit interleukin 6 (IL-6) and tumor necrosis factor (TNF)-alpha.

    View the full report here:

    https://www.thebusinessresearchcompany.com/report/acute-respiratory-distress-syndrome-ards-global-market-report

    How Is the Acute Respiratory Distress Syndrome (ARDS) Market Conceptually Defined?

    Acute respiratory distress syndrome (ARDS) is a potentially fatal illness characterized by non-compliant, or stiff lungs and low oxygenation. It is an acute, diffuse and inflammatory form of lung injury that can occur in seriously ill patients. Acute respiratory distress syndrome (ARDS) treatment involves mechanical ventilation with low tidal volumes and positive end-expiratory pressure (PEEP) to support oxygenation and prevent lung injury.

    Purchase the full report and get a swift delivery:

    https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=13005

    About The Business Research Company:

    With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

    Get in touch with us:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas +1 310-496-7795

    Europe +44 7882 955267

    Asia & Others +44 7882 955267 & +91 8897263534

    Email us at info@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model